RenovoRx ( (RNXT) ) has released a notification of late filing.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
RenovoRx, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the need to complete certain technical accounting requirements with both current and former auditing firms. The company expects to file the report within the fifteen-day grace period allowed by the SEC. RenovoRx anticipates recognizing initial revenue from its RenovoCath commercial efforts and a slight decrease in net loss due to reduced expenses. These figures are still under review and may change upon final filing. The notification was signed by Ronald B. Kocak, Vice President, Controller, and Principal Accounting Officer, indicating ongoing compliance efforts.
More about RenovoRx
YTD Price Performance: -26.47%
Average Trading Volume: 139,701
Technical Sentiment Signal: Buy
Current Market Cap: $35.57M
For detailed information about RNXT stock, go to TipRanks’ Stock Analysis page.